Methaqualone
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Methaqualone — Quaaludes, ludes, Mandrax — is a synthetic depressant of the quinazolinone class. It was marketed as a safer alternative to barbiturates but proved comparably dangerous. It enhances GABA, the brain's main inhibitory signaling system, producing sedation, muscle relaxation, and a distinctive physical euphoria.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, barbiturates, alcohol +2 morebenzodiazepines, barbiturates, alcohol, GHB, GABAergic depressants show less
Methaqualone was first synthesized in 1951 during antimalarial research in India.[2] By 1965 it was the most prescribed sedative in Britain and a top-selling sleep drug in the United States.[3] Legal manufacture ended worldwide in 1984; it persists as a major illicit drug in South Africa, smoked with cannabis as Mandrax.[4]
Subjective effects include warm sedation, muscle relaxation, euphoria, disinhibition, and a distinctive tingling in the lips and fingertips.[5] The experience is defined by bodily heaviness and emotional openness — social barriers dissolve and the body sinks into deep relaxation. Amnesia, impaired coordination, and a powerful compulsive redosing urge are characteristic unwanted effects.[6]
Methaqualone produces rapid physical dependence and can kill through respiratory depression at higher doses.[7] Tolerance builds along two independent routes, driving dose escalation; combining it with alcohol dramatically amplifies the risk for at least three days after use.[8][9] Its mechanism is well established through decades of clinical research and 2024 structural studies, though some pharmacokinetic details remain unresolved.[10][11]
History[edit]
Discovery
Methaqualone was first synthesized in 1951 by Indra Kishore Kacker and Syed Husain Zaheer during antimalarial research in India.[2] Its sedative properties quickly overshadowed its antimalarial potential. By 1955 it was being marketed as a non-addictive alternative to barbiturate sleeping pills.[2]
Clinical and commercial significance
Commercial sales began in the UK in 1960 under the brand names Melsed, Melsedin, and Renoval.[3] By 1965, methaqualone was Britain's most prescribed sedative, and Quaalude was among the top-selling sedatives in the United States.[12] The UK formulation Mandrax combined methaqualone with diphenhydramine to strengthen its hypnotic effect.[13][12]
Prohibition and persistence
The UK banned it under the Misuse of Drugs Act in 1971.[2] The United States moved it to Schedule I in 1984, ending legal manufacture everywhere.[7][3] Today methaqualone persists in South Africa — crushed and smoked with cannabis through the "white pipe" — as one of the country's most prevalent illicit drugs,[14][4] with 17% of at-risk young women in Cape Town testing positive as recently as 2024.[15]
The name Quaalude is a portmanteau of "quiet interlude," coined by manufacturer William H. Rorer Inc. Tablets imprinted with the number "714" became cultural shorthand for the drug, known colloquially as "Lemmons" or "714s".[12] In South Africa, the name Mandrax outlived the brand itself, becoming the generic term for all illicit methaqualone regardless of formulation or source.
Chemistry[edit]
Structural class
Methaqualone belongs to the quinazolinone chemical class — compounds built around a fused bicyclic ring structure.[16] It has moderate fat-solubility (XLogP 2.5), allowing it to cross into the brain quickly after ingestion.[17]
Molecular identity
| Molecular formula | C₁₆H₁₄N₂O |
| Molecular weight | 250.29 g/mol |
Related quinazolinone compounds include the research derivative PPTQ, which acts at the same receptor site in the brain,[18] and the novel psychoactive substance SL-164, which appeared on unregulated markets around 2019.[19]
Pharmacology[edit]
Mechanism of action
Methaqualone enhances GABA, the brain's primary inhibitory signal, by acting as a positive allosteric modulator of GABAA receptors.[1] It does not activate the receptor directly — it amplifies the receptor's response to GABA already present. A 2024 atomic-resolution imaging study showed it binds at a specific site in the receptor's membrane-spanning region, the same site used by the general anesthetic etomidate.[10]
The effect follows an orderly dose-response: anticonvulsant activity at low doses, muscle relaxation before sedation, and sedation last.[13] The compound has negligible activity at other neurotransmitter systems.[1]
Pharmacokinetics
After swallowing, methaqualone is absorbed rapidly and almost completely — about 99% within two hours.[12][20] The liver breaks down more than 95% of each dose into several hydroxylated metabolites.[21][22] The half-life is disputed — controlled studies report about 10 hours,[11] while other sources cite 20–60 hours, likely reflecting a two-phase processing pattern.[23]
Neuroscience[edit]
Where it acts
In the cortex, enhanced GABA signaling drives the progression from relaxation through sedation to unconsciousness.[1] In the somatosensory cortex specifically, the drug changes how neurons respond to touch — producing the distinctive tingling in lips and fingertips.[5] GABA receptors in the spinal cord and brainstem underlie the muscle relaxation, which appears at lower doses than sedation.[13]
Why it matters
Methaqualone's euphoric effect is stronger than that of diazepam in controlled testing.[6] Enhanced GABA signaling in reward circuits releases a brake on dopamine neurons, increasing dopamine in the brain's pleasure centers — the same reward mechanism as benzodiazepines, barbiturates, and alcohol. Methaqualone's higher abuse liability may reflect its engagement of an additional receptor pathway those drugs cannot reach.[1]
Paradoxical convulsions in overdose[7] are unusual for a drug that enhances inhibitory signaling, and their cause remains unresolved. A delayed withdrawal — insomnia, seizures, and delirium emerging 1–3 weeks after overdose[24] — suggests the drug persists in brain tissue long after blood levels clear. No neuroimaging data exist for the smoked "white pipe" route, leaving that method's rapid-onset effects uncharacterized.
Subjective Effects[edit]
Methaqualone produces a warm, heavy sedation combined with a distinctive tactile euphoria — tingling in the lips and fingertips — that sets it apart from other sedatives. Anxiety disappears, social barriers dissolve, and the body settles into deep physical relaxation. The disinhibitory quality amplifies the social or solitary character of the environment.
Among sedatives, it most closely resembles a strong benzodiazepine in anxiolytic quality but produces more euphoria and greater disinhibition.[6] For overdose risk, it behaves more like a barbiturate — there is no reliable ceiling on respiratory depression.
Effect Grid
The full sedative-hypnotic profile manifests. Pronounced muscle relaxation and euphoria dominate the experience — controlled studies confirm methaqualone produces greater euphoria than diazepam at comparable doses. Anxiety suppression is strong. Disinhibition becomes prominent, with reduced impulse control and social inhibitions.
Tactile euphoria reaches its characteristic expression: peripheral tingling spreads across lips, fingertips, and genitalia. The body feels heavy and warm. Motor control impairment is clearly evident — gait becomes unsteady. Dizziness and vestibular distortion may occur. Sexual arousal enhancement is commonly reported, likely mediated by disinhibition rather than direct pharmacological effect.
Cognitive slowing is marked. Mild amnesia may develop for events during the experience. Compulsive redosing urge is present at this level — the desire to take more can be strong. Analysis suppression and thought deceleration are prominent. Do not drive or operate machinery.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Visual acuity suppression · Proprioceptive distortion · Visual processing suppression · Internal hallucinations
Internal hallucinations
Dizziness · Body high · Physical fatigue · Sexual arousal enhancement · Bodily heaviness · Nystagmus (eye wobbles) · Nausea · Dry mouth · Constipation · Involuntary body movements · Trembling
Bodily heaviness · Nystagmus (eye wobbles) · Nausea · Dry mouth · Constipation · Involuntary body movements · Trembling
Cognitive euphoria · Focus suppression · Information processing suppression · Cognitive fatigue · Language suppression · Compulsive redosing urge · Confusion · Memory suppression · Motivation suppression · Thought disorganization · Aesthetic enhancement · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Cognitive fatigue · Language suppression · Confusion · Memory suppression · Motivation suppression · Thought disorganization · Aesthetic enhancement · Delusions of sobriety · Memory fragmentation · Amnesia · Delirium
Timeline
Initial absorption begins. Subtle anxiolysis and a faint sense of calm may emerge as methaqualone crosses the blood-brain barrier. Effects are sub-threshold for most users.
Progressive sedation and muscle relaxation build. Peripheral tingling in lips and fingertips emerges — the characteristic somatosensory signature. Euphoria and anxiolysis become clearly perceptible.
Full sedative-hypnotic, euphoric, and tactile effect profile. Maximum disinhibition, muscle relaxation, and tactile euphoria. Motor impairment evident.
Gradual reduction in euphoria and sedation intensity. Residual muscle relaxation and drowsiness persist. Motor impairment slowly improves but remains present.
Residual drowsiness, cognitive slowing, and potential hangover. Alcohol sensitivity remains elevated for up to 3 days post-dose.
⚠ Do not drive or operate machinery for at least 24 hours after use.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Severefatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · barbiturates · alcohol
Toxicity
Acute toxicity
No human lethal dose has been established through controlled data. The only animal LD50 is 240 mg/kg in mice,[25] which does not translate directly to human oral dosing. Doses above 300 mg oral may produce dangerous effects in individuals without tolerance,[6] though this threshold lacks formal determination. safety citation needed
Overdose presentation
Methaqualone overdose produces unconsciousness, respiratory depression, metabolic acidosis, and low potassium.[26] In a large case review of non-barbiturate hypnotic poisonings, 6 deaths occurred among 349 cases.[27] Unlike most sedative overdoses, methaqualone can also cause convulsions, delirium, and dangerous overheating.[7]
Respiratory depression
Slowing of breathing is the primary life-threatening effect, shared by all drugs that enhance GABA signaling.[7] No established antidote exists for methaqualone overdose. Treatment is supportive — airway management and monitoring.
Late post-overdose syndrome
A dangerous delayed reaction can emerge 1–3 weeks after methaqualone overdose: insomnia, restlessness, seizures, and delirium.[24] The drug persists in brain tissue long after blood levels clear, producing physical dependence even following a single overdose event. Recovery from methaqualone overdose requires monitoring well beyond the acute phase.
Psychological risks
The primary psychological danger is disinhibition-driven harm. Suppression of prefrontal function impairs judgment, decision-making, and impulse control.[7] In South Africa, use is linked to sexual risk-taking, reduced ability to negotiate safer sex, higher HIV transmission,[28] and drug-facilitated sexual assault.[29]
Amnesia at higher doses creates blackout periods during which behavior continues but no memory forms. Combined with disinhibition, this creates a high-risk profile for harm to self and others. Compulsive redosing[6] is a documented pharmacological feature, not a personal failing, and drives escalating use.
Tolerance & dependence
Tolerance develops along two independent pathways. Receptors adapt at the cellular level within weeks,[30] and the liver simultaneously increases its rate of methaqualone breakdown — in dependent patients, producing some of the fastest drug metabolism measured in any substance-dependent group.[9] These routes compound each other, driving dose escalation faster than either alone.
Physical dependence is confirmed in animals[30][31] and humans.[9] Withdrawal is medically dangerous — seizures are the most serious risk, comparable to barbiturate or benzodiazepine withdrawal, with insomnia, restlessness, elevated REM sleep, and delirium possible 1–3 weeks post-exposure.[24] Cross-tolerance extends to barbiturates,[32] benzodiazepines, alcohol, and GHB. Controlled testing found abuse-liability scores significantly above diazepam.[6]
Drug interactions
Alcohol
The methaqualone-alcohol combination is the most dangerous and best-documented interaction. Alcohol lowers the effective dose of methaqualone in the brain, independent of how either drug is processed by the liver,[8] and also slows methaqualone elimination, prolonging its effects.[33] In mice, methaqualone extended alcohol-induced unconsciousness by 269%.[25]
GABAergic depressants
All GABA-enhancing drugs — benzodiazepines, barbiturates, GHB, anesthetics — carry additive or synergistic respiratory depression risk in combination with methaqualone.[7]
Baclofen
safety citation needed
Opioids
Opioids suppress breathing through a completely separate pathway in the brainstem, producing multiplicative rather than merely additive respiratory risk when combined with methaqualone.[7]
Cannabis
The South African "white pipe" method combines methaqualone with cannabis.[14] No controlled studies of this combination exist. Combustion products from the pipe method may contribute additional respiratory harm.
Contraindications
Absolute contraindications
- Concurrent use of other CNS depressants (alcohol, benzodiazepines, barbiturates, opioids, GHB, baclofen): synergistic respiratory depression risk renders any combination potentially lethal.[7]
- Respiratory insufficiency: pre-existing breathing impairment amplifies methaqualone's dose-dependent respiratory depression.
- Seizure disorders: paradoxical convulsions are documented in overdose;[7] withdrawal also lowers seizure threshold.
Relative contraindications
- Liver impairment: impaired liver function prolongs drug exposure and increases toxicity risk.
- Pregnancy: methaqualone crosses the placental barrier; pharmacokinetics are altered during pregnancy and labor.[35]
- History of substance use disorders: high abuse liability[6] and compulsive redosing make methaqualone high-risk for individuals with dependence vulnerability.
- Concurrent CYP3A4 inhibitors: drugs that slow liver metabolism (ketoconazole, erythromycin, grapefruit juice) would be expected to increase methaqualone levels and toxicity risk. inferred
Harm Reduction[edit]
Forms & Identification
All current methaqualone is clandestinely manufactured[36] — no batch carries any assurance of identity or purity. Tablets sold as Mandrax in South Africa routinely contain variable methaqualone amounts alongside unknown adulterants. Standard drug screening panels may not detect related quinazolinone compounds such as SL-164[19] — a negative screen does not confirm the absence of such substances. Quantitative analysis (GC-MS or LC-MS) is the most reliable identification method.
Guidelines
- Test any material before use with reagent kits and, where accessible, quantitative analysis.
- Start with the lowest plausible dose and wait at least 3 hours before considering redosing — oral absorption is complete but onset can be gradual.
- Do not combine with alcohol, opioids, benzodiazepines, or any other depressant.
- Arrange a sober sitter, particularly at doses above the threshold range.
- Eat a light meal beforehand to moderate absorption rate.
- Have a clear plan for where and how sleep will happen — methaqualone produces strong sedation and motor impairment that escalates over the session.
- The compulsive redosing urge is a documented pharmacological feature of this compound,[6] not a personal failing — decide on a dose before onset and remove remaining supply from immediate access.
Set & Setting
Methaqualone's pronounced disinhibition and amnesia make environmental control especially important. A familiar, low-stimulation setting with trusted companions reduces the risk of disinhibition-driven harm. The drug progressively impairs motor coordination and judgment — a sober companion who can monitor for respiratory depression and prevent dangerous behavior is strongly recommended. Settings involving water, heights, or driving are dangerous.
Aftercare & integration. The day after methaqualone use commonly brings residual sedation, cognitive fog, and low mood. Prioritize sleep, hydration, and light nutrition. Avoid alcohol for at least three full days — the interaction window extends well beyond the subjective effects.[34]
If blackout periods occurred, significant decisions or actions may have taken place without memory formation. Check in with people present during the experience to help reconstruct events. Repeated amnesia or compulsive redosing are signals that the substance is producing harm regardless of subjective enjoyment — they warrant honest self-assessment and, if patterns persist, professional consultation.
Recovery & Support
Methaqualone withdrawal is medically dangerous — seizures are the most serious risk, comparable to barbiturate or benzodiazepine withdrawal. Do not attempt abrupt cessation after regular use without medical supervision. A medically supervised taper, typically using a long-acting benzodiazepine or phenobarbital under clinical guidance, is the standard approach to GABAergic depressant withdrawal.
Support resources include SAMHSA's National Helpline (US: 1-800-662-4357), local addiction medicine services, and peer support communities. In South Africa, the South African National Council on Alcoholism and Drug Dependence (SANCA) provides regional treatment referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between heavy sedation and dangerous overdose is narrow with methaqualone. Seek immediate medical help if any of the following occur:
- Breathing becomes slow, shallow, irregular, or stops
- The person cannot be woken by loud voice or firm sternum rub
- Lips, fingertips, or skin turn blue or gray
- Seizures or convulsions occur — unusual for most sedatives but documented with methaqualone[7]
- Body temperature rises sharply (hot, dry skin)
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position (on their side, mouth angled downward) to prevent choking.
- 3. Monitor breathing continuously until help arrives.
- 4. Do NOT induce vomiting.
- 5. Do NOT leave the person alone.
What to tell the dispatcher: Name the substance (methaqualone, Mandrax, or Quaalude), estimated amount taken, time of ingestion, any other substances used (especially alcohol), and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agents: No established antidote exists for methaqualone overdose. Treatment is supportive — airway management and monitoring.
Legal Status[edit]
Methaqualone is prohibited in all major jurisdictions worldwide, with no jurisdiction currently permitting therapeutic use.[3] All current supply is clandestinely manufactured.[36]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Schedule II from 1973; reclassified Schedule I in 1984. No accepted medical use.[3][36] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Withdrawn from clinical market in early 1980s following documented addiction and lethal overdoses.[2] |
| Canada | Schedule III (CDSA) | Controlled; no longer manufactured or clinically available. |
| Australia | Schedule 9 (Prohibited Substance) | Highest restriction category; no licensed manufacture, supply, or use. |
| European Union | Generally prohibited (varies by member state) | Restricted or prohibited in all member states. |
| South Africa | Illegal | Prohibited despite widespread illicit availability; Mandrax remains one of the most commonly seized illicit drugs.[4] |
| United Nations | Schedule II (Convention on Psychotropic Substances) | Initially placed in Schedule I; moved to Schedule II in 1979.[3] |
Analog act considerations
In the United States, novel quinazolinone analogs such as SL-164 may fall under the Federal Analogue Act if marketed for human consumption, though standard drug screening panels may not detect these analogs.[19]
references
- [1] ^abcdeHammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voss A, Jensen AA (2015) A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) — Molecular Pharmacology doi:10.1124/mol.115.099291
- [2]
- [3]
- [4] ^abcParry CD, Bhana A, Pluddemann A, Myers B, Siegfried N, Morojele NK, Flisher AJ, Kozel NJ (2002) The South African Community Epidemiology Network on Drug Use (SACENDU): description, findings (1997-99) and policy implications — Addiction PMID:12144599
- [5] ^abHicks TP, Kaneko T, Oka JI (1990) Receptive-field size of S1 cortical neurones is altered by methaqualone via a GABA mechanism — Canadian Journal of Neurological Sciences PMID:2311013
- [6]